Physiologically based pharmacokinetic modelling of lisinopril in children: A case story of angiotensin converting enzyme inhibitors.

British Journal of Clinical Pharmacology
Feifan XieAn Vermeulen

Abstract

Lisinopril is an angiotensin converting enzyme inhibitor to treat hypertension. It shows complex pharmacokinetics (PK), and its PK behaviour in paediatric populations is not well characterized. The aim of this study was to develop a physiologically based PK (PBPK) model for lisinopril to describe the drug's PK in children. The PBPK model development was performed in a step-wise manner. An adult model was initially developed to characterize lisinopril's disposition and absorption and verified using literature data. Subsequently, the adult PBPK model was extrapolated to the paediatric population (0.5-18 years old) by accounting for age-dependent physiological and anatomical changes. Model performance was evaluated by comparing the PK profiles and drug exposures of observed vs predicted data. The disposition of lisinopril was well described by a minimal PBPK model-an effective strategy to capture the biphasic elimination of the drug. The absorption of lisinopril was described by the intestinal peptide transporter-mediated uptake. The adult model adequately described the literature data with predictions within a twofold range of clinical observations. Good model predictivity was also observed in children older than 6 years of age. ...Continue Reading

References

Feb 1, 1989·British Journal of Clinical Pharmacology·A E TillM Hichens
Jan 1, 1989·Pharmacotherapy·S L Chase, J D Sutton
Jul 1, 1989·Biopharmaceutics & Drug Disposition·B BeermannI Junggren
Sep 23, 1988·The American Journal of Medicine·B Beermann
Dec 1, 1988·Journal of Pharmaceutical Sciences·M Hu, G L Amidon
Sep 1, 1982·British Journal of Clinical Pharmacology·E H UlmJ L Schelling
Dec 1, 1984·Journal of Pharmacokinetics and Biopharmaceutics·Y SawadaT Iga
Aug 1, 1981·Journal of Pharmacokinetics and Biopharmaceutics·L B Sheiner, S L Beal
Jan 1, 1994·European Journal of Clinical Pharmacology·M NeubeckE Mutschler
Jan 6, 1999·Journal of Pharmaceutical Sciences·J D IrvineJ R Grove
Jul 7, 1999·Journal of Pharmaceutical Sciences·J Wang, D R Flanagan
Feb 9, 2002·Journal of Pharmaceutical Sciences·Jianzhuo Wang, Douglas R Flanagan
Mar 31, 2004·International Journal of Clinical Pharmacology and Therapeutics·H Y ChoY B Lee
Sep 1, 2004·Lancet·Patrina H Y CaldwellJonathan C Craig
Apr 29, 2005·Journal of Pharmaceutical Sciences·Trudy RodgersMalcolm Rowland
Aug 3, 2005·Biopharmaceutics & Drug Disposition·J J I TamimiRuwayda Dham
Jan 10, 2006·BMC Clinical Pharmacology·David G Levitt, Rik C Schoemaker
Aug 25, 2006·Clinical Pharmacokinetics·Trevor N JohnsonGeoffrey T Tucker
Sep 21, 2006·Clinical Pharmacokinetics·Andrea N EdgintonStefan Willmann
Jan 12, 2007·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Ronald J HoggShahnaz Shahinfar
Oct 31, 2007·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·H Lennernäs
Apr 22, 2009·The AAPS Journal·Masoud JameiGeoffrey Tucker
Oct 30, 2014·CPT: Pharmacometrics & Systems Pharmacology·A R Maharaj, A N Edginton
Mar 27, 2015·Clinical Pharmacology and Therapeutics·H TrachtmanUNKNOWN Best Pharmaceuticals for Children Act-Pediatric Trials Network Administrative Core Committee
Aug 25, 2015·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jennifer E SagerNina Isoherranen
Apr 16, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Miriam G MooijSaskia N de Wildt
Apr 16, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nitin MehrotraVikram Sinha
Sep 30, 2016·Archives of Disease in Childhood·Evelien SnauwaertPauline De Bruyne
Dec 16, 2016·Biopharmaceutics & Drug Disposition·Jean-Marie NicolasAnna-Lena Ungell
Oct 22, 2017·British Journal of Pharmacology·Stephen Ph AlexanderUNKNOWN CGTP Collaborators
Feb 15, 2018·The AAPS Journal·Ian E TempletonLuna Musib
Apr 21, 2018·Archives of Disease in Childhood·Charlotte I S BarkerMartin Offringa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Journal of Pharmacokinetics and Pharmacodynamics
Xiaofeng Wang, Brian E Davies
Medicina : revista della Enciclopedia medica italiana
The Medical Letter on Drugs and Therapeutics
© 2021 Meta ULC. All rights reserved